Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07050511 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants
A Phase 1 study of SARS-CoV-2, sponsored by Generate Biomedicines.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT07050511 is a Phase 1 study of SARS-CoV-2 that has completed, run by Generate Biomedicines. The registered enrollment target is 51 participants, below the 3,768-participant average among 28 other SARS-CoV-2 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07050511, a Phase 1 study of SARS-CoV-2, has completed, sponsored by Generate Biomedicines.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to test the safety and tolerability of a single ascending dose (SAD) of GB-0669 administered intravenously in adults. The goal of this study is also to measure the blood levels of GB-0669 in the body. Study participants will be assigned to receive the study drug or placebo (the placebo is called saline; it is a liquid like salt water and made to look like the study drug but contains no active ingredient). The study is blinded, which means you and the study doctor will not know whether you are getting the study drug or placebo. Study participants will be assigned to one of 5 cohorts (study groups). Each cohort will have a single ascending dose (SAD). The first two SAD cohorts will have 3 study participants receiving GB-0669 and 3 study participants receiving placebo. The last three SAD cohorts will have 10 study participants receiving GB-0669 and 3 study participants receiving placebo. The SAD cohort dose levels will be as follows: 100 mg, 300 mg, 600 mg, 1200 mg, 2400 mg.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GB-0669
Study Locations (1)
Massachusetts
- Generate Biomedicines - Somerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2023-07-18 |
| Est. Completion | 2024-11-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07050511
The ClinicalTrials.gov registry entry for NCT07050511 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,768-participant average among 28 other SARS-CoV-2 trials with a reported enrollment target (99% lower). The listed sponsor is Generate Biomedicines, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SARS-CoV-2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07050511 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07050511 about?
NCT07050511 is a clinical study titled "Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants". The goal of this clinical trial is to test the safety and tolerability of a single ascending dose (SAD) of GB-0669 administered intravenously in adults. The goal of this study is also to measure the blood levels of GB-0669 in the body. Study participants will be assigned to receive the study drug o...
What is the current status of trial NCT07050511?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2023-07-18. Estimated completion is 2024-11-22.
What conditions does trial NCT07050511 study?
This clinical trial studies the following conditions: SARS-CoV-2.
What interventions are being tested in trial NCT07050511?
The interventions under investigation include: Placebo (DRUG), GB-0669 (DRUG).
Who is sponsoring clinical trial NCT07050511?
This trial is sponsored by Generate Biomedicines, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07050511 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV-2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
RECRUITING · Phase 1
-
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
COMPLETED · Phase 1
-
A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.
COMPLETED · Phase 1
-
Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
COMPLETED · Phase 1
-
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.